David L. Becton
Role not yet determined Is this you? Add your title
Also affiliated: University of Southern California (2008); Cincinnati Children's Hospital Medical Center (2008); American Cancer Society (1986); Monroe Carell Jr. Children's Hospital (2005); Arkansas Children's Hospital (1987–2025); St. Jude Children's Research Hospital (2002–2008); Lucile Packard Children's Hospital (2008); Children's Hospital of Philadelphia (2008); Johns Hopkins University (2005); Emory University (2008); Duke University (1984–2008); Wayne State University (2005); University of Washington (2004); Washington University in St. Louis (2002); University of Arkansas Medical Center (2006–2018); University of California San Diego (2002); Massachusetts General Hospital (2004–2005); Fred Hutch Cancer Center (2004); The Barbara Ann Karmanos Cancer Institute (2005); Duke Medical Center (1984–2008); Children's Hospital of Michigan (1999–2008); University of California San Diego Medical Center (2002); Children's Oncology Group (2004–2005); Washington University Medical Center (2002); Stanford Medicine (2001–2005); Children's Healthcare of Atlanta (2008); Sidney Kimmel Comprehensive Cancer Center (2005); Arkansas Children's Research Institute (2021); Virginia Commonwealth University Medical Center (2005–2008); Texas Tech University Health Sciences Center (2024); Stanford University (2001–2008)
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
David L. Becton's research focuses on acute myeloid leukemia (AML) in pediatric patients, with a particular emphasis on gene expression profiles and their correlation with clinical outcomes and treatment sensitivity. He has investigated the prevalence and prognostic significance of KIT mutations in children with core binding factor AML, as well as the expression of chromosome 21-localized genes in both Down syndrome and non-Down syndrome AML blast cells and their relationship to in vitro drug sensitivity.
His work also includes studies on the impact of disease risk on the efficacy of bone marrow transplantation for pediatric AML. Becton has contributed to the understanding of gene expression profiles at diagnosis in de novo childhood AML patients, identifying FLT3 mutations associated with favorable clinical outcomes. Additionally, his research has explored the differential gene expression, GATA1 target genes, and chemotherapy sensitivity in Down syndrome megakaryocytic leukemia. Becton has also published on discontinuing penicillin prophylaxis in children with sickle cell anemia.
With an h-index of 28 and over 90 publications, Becton is recognized as a highly cited researcher. He collaborates with several colleagues at the University of Arkansas for Medical Sciences, including P. Strebeck, Jason E. Farrar, Lauren Banko, and Megan S. Evans.
Metrics
- h-index: 28
- Publications: 92
- Citations: 2,960
Selected Publications
-
Mental Health Evaluation in Patients with Vascular Malformations (2026)
-
Severe transient abnormal myelopoiesis in a premature neonate with Trisomy 21: a rare, fatal presentation with complex therapeutic challenges (2026)
-
Intracranial Hypotension in Pediatric Oncology Patients Following Lumbar Puncture: A Case Series (2025)
-
Violaceous Nodules in an Infant With Noonan Syndrome: Challenge (2025)
-
Violaceous Nodules in an Infant With Noonan Syndrome: Answer (2025)
-
Anemia as a presenting sign for gastrinoma (2024)
-
Infection masking leukemia (2024)
-
Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital (2021)
-
Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography (2020)
-
Short‐term side effects and patient‐reported outcomes of bleomycin sclerotherapy in vascular malformations (2018)
-
Nutlin‐3 treatment spares cisplatin‐induced inhibition of bone healing while maintaining osteosarcoma toxicity (2016)
-
Cisplatin inhibits bone healing during distraction osteogenesis (2013)
-
Cardiac Myeloid Sarcoma (2011)
-
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML (2010)
-
Index of Suspicion (2009)
Grants & Funding
As listed on this researcher's institutional profile.
- Prevention of Complications of Hemophilia Centers for Disease Control & Prevention
- PROPHYLACTIC PENICILLIN IN SICKLE CELL DISEASE NIH/NHLBI
- PEDIATRIC ONCOLOGY GROUP NIH
Collaboration Network
Top Collaborators
- Cisplatin inhibits bone healing during distraction osteogenesis
- Efficacy of continuous infusion 2‐CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis
- Reconversion of bone marrow in Gaucher disease treated with enzyme therapy documented by MR
- Use of FEIBA for Invasive or Surgical Procedures in Patients With Severe Hemophilia A or B With Inhibitors
- Treatment of Deep Vein Thrombosis With Enoxaparin in Pediatric Cancer Patients Receiving Chemotherapy
Showing 5 of 10 shared publications
- Natural History of Histiocytosis-X
- An experience with an implanted port system in 66 children with cancer
- Acute-phase reactants in sickle cell disease
- CRYOPRECIPITATE: A SAFE FACTOR VIII REPLACEMENT
- Single institution experience with high‐dose cyclophosphamide, continuous infusion vincristine, escalating doses of VP‐16‐213, and total body irradiation with unpurged bone marrow rescue in children with neuroblastoma
Showing 5 of 6 shared publications
- Efficacy of continuous infusion 2‐CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis
- Treatment of Deep Vein Thrombosis With Enoxaparin in Pediatric Cancer Patients Receiving Chemotherapy
- Long‐term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate
- KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts
- IL-12 induces apoptosis of Ewing's sarcoma cell line in vitro
Showing 5 of 6 shared publications
- An experience with an implanted port system in 66 children with cancer
- CRYOPRECIPITATE: A SAFE FACTOR VIII REPLACEMENT
- Single institution experience with high‐dose cyclophosphamide, continuous infusion vincristine, escalating doses of VP‐16‐213, and total body irradiation with unpurged bone marrow rescue in children with neuroblastoma
- Thrombotic Thrombocytopenic Purpura in an Asplenic Patient with Hereditary Spherocytosis
- Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
- Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000
- Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia
- Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).
- Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
- Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000
- Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia
- Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).
- Cisplatin inhibits bone healing during distraction osteogenesis
- Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography
- Nutlin‐3 treatment spares cisplatin‐induced inhibition of bone healing while maintaining osteosarcoma toxicity
- Efficacy of continuous infusion 2‐CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis
- Long‐term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate
- C-Reactive Protein and Soluble IL-2Receptor Correlate with High Risk of Clinical Sepsis Among Children with Fever and Neutropenia.
- Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
- Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000
- Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).
- Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
- Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000
- Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).
- Cardiac Myeloid Sarcoma
- Index of Suspicion
- C-Reactive Protein and Soluble IL-2Receptor Correlate with High Risk of Clinical Sepsis Among Children with Fever and Neutropenia.
- Short‐term side effects and patient‐reported outcomes of bleomycin sclerotherapy in vascular malformations
- Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography
- Intracranial Hypotension in Pediatric Oncology Patients Following Lumbar Puncture: A Case Series
- Short‐term side effects and patient‐reported outcomes of bleomycin sclerotherapy in vascular malformations
- Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography
- Mental Health Evaluation in Patients with Vascular Malformations
- Anemia as a presenting sign for gastrinoma
- Violaceous Nodules in an Infant With Noonan Syndrome: Answer
- Violaceous Nodules in an Infant With Noonan Syndrome: Challenge
- Cisplatin inhibits bone healing during distraction osteogenesis
- Nutlin‐3 treatment spares cisplatin‐induced inhibition of bone healing while maintaining osteosarcoma toxicity
Similar Researchers
Based on overlapping research topics